← Leaderboards
Qingguo Xu
Virginia Commonwealth University
$4,396,626
Attributed
$7,418,775
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,418,775 · 6
By mechanism
R01$4,825,351 · 3
UG3$2,185,247 · 2
R21$408,177 · 1
Top collaborators
- Jian-Xing Ma6 shared
- Marina Gorbatyuk2 shared
- Maria B Grant2 shared
- Matthew Sean Halquist1 shared
- Frederick Gerard Moeller1 shared
- Charles O'Keeffe1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Frederick Gerard Moeller$65,095,599
- Matthew Sean Halquist$1,629,321
- Charles O'Keeffe$403,667
- Diane Ingabire$48,974
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DosePharmaceutical PreparationsFormulationIn VitroLeadDrug KineticsIn VivoFutureRattusPreventionOryctolagus CuniculusParticle SizeAnimalsDrug Delivery SystemsSafetyMonitorNanoparticleReproducibilityClinical TranslationInjectionsToxic EffectAnimal ModelBlindnessInflammation
Grant awards (16)
Fenofibrate microemulsion for treating nitrogen mustard induced corneal injury$570,579
UG3 · FY2025 · EY · contact PI
RXR-based therapy for diabetic retinopathy$559,365
R01 · FY2025 · EY
Sustained release of fenofibrate for the treatment of diabetic retinopathy$538,028
R01 · FY2025 · EY · contact PI
DSP nanoparticles for treating nitrogen mustard induced corneal injury$184,682
R21 · FY2025 · EY · contact PI
Sustained release of fenofibrate for the treatment of diabetic retinopathy$23,288
R01 · FY2025 · EY · contact PI
Sustained release of fenofibrate for the treatment of diabetic retinopathy$538,028
R01 · FY2024 · EY · contact PI
DSP nanoparticles for treating nitrogen mustard induced corneal injury$223,495
R21 · FY2024 · EY · contact PI
RXR-based therapy for diabetic retinopathy$87,513
R01 · FY2024 · EY
Sustained release of fenofibrate for the treatment of diabetic retinopathy$538,028
R01 · FY2023 · EY · contact PI
Sustained release of fenofibrate for the treatment of diabetic retinopathy$551,841
R01 · FY2022 · EY · contact PI
New method to treat or prevent corneal graft rejection$385,756
R01 · FY2021 · EY · contact PI
New method to treat or prevent corneal graft rejection$397,688
R01 · FY2020 · EY · contact PI
Novel LAAM formulations to treat Opioid Use Disorder (UG3 DA048768-01A1)$1,614,668
UG3 · FY2019 · DA · contact PI
New method to treat or prevent corneal graft rejection$397,659
R01 · FY2019 · EY · contact PI
New method to treat or prevent corneal graft rejection$397,344
R01 · FY2018 · EY · contact PI
New method to treat or prevent corneal graft rejection$410,813
R01 · FY2017 · EY · contact PI